Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

The Lancet 2026

View at publisher
Authors: Julio Rosenstock, LIANA K. BILLINGS, Reena Gajria, FRANCESCO GIORGINO, Nanna B. Johansen, Klara R Klein, Usha K Thamattoor, John B Buse, Akshay B Jain
DOI: 10.1016/s0140-6736(26)01022-6
Cited by: 7
References: 28

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Metabolism and Cancer

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
408
Issue
10549
Pages
38–51
Publication date
7 June 2026
Language
EN